JP2021514206A5 - - Google Patents
Info
- Publication number
- JP2021514206A5 JP2021514206A5 JP2020566543A JP2020566543A JP2021514206A5 JP 2021514206 A5 JP2021514206 A5 JP 2021514206A5 JP 2020566543 A JP2020566543 A JP 2020566543A JP 2020566543 A JP2020566543 A JP 2020566543A JP 2021514206 A5 JP2021514206 A5 JP 2021514206A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- human
- binding
- cancer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135326A JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632756P | 2018-02-20 | 2018-02-20 | |
| US62/632,756 | 2018-02-20 | ||
| PCT/US2019/018748 WO2019164929A1 (en) | 2018-02-20 | 2019-02-20 | Antibody variable domains targeting cd33, and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135326A Division JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514206A JP2021514206A (ja) | 2021-06-10 |
| JP2021514206A5 true JP2021514206A5 (https=) | 2022-03-10 |
| JP7539840B2 JP7539840B2 (ja) | 2024-08-26 |
Family
ID=67688433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566543A Active JP7539840B2 (ja) | 2018-02-20 | 2019-02-20 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
| JP2024135326A Pending JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135326A Pending JP2024170430A (ja) | 2018-02-20 | 2024-08-14 | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200376034A1 (https=) |
| EP (1) | EP3755348A4 (https=) |
| JP (2) | JP7539840B2 (https=) |
| KR (1) | KR20200133222A (https=) |
| CN (1) | CN111989109A (https=) |
| AU (1) | AU2019225740A1 (https=) |
| BR (1) | BR112020016944A2 (https=) |
| CA (1) | CA3091764A1 (https=) |
| CL (2) | CL2020002143A1 (https=) |
| EA (1) | EA202091976A1 (https=) |
| IL (1) | IL276776A (https=) |
| MX (1) | MX2020008683A (https=) |
| PE (1) | PE20211224A1 (https=) |
| SG (1) | SG11202007943RA (https=) |
| TW (1) | TW201945390A (https=) |
| WO (1) | WO2019164929A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| PE20221316A1 (es) * | 2019-10-15 | 2022-09-07 | Dragonfly Therapeutics Inc | Proteinas que se unen a nkg2d, cd16 y flt3 |
| JP7512394B2 (ja) * | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20250082681A1 (en) * | 2021-07-30 | 2025-03-13 | Nanjing Legend Biotech Co., Ltd. | Antibodies against cll1 and constructs thereof |
| WO2023015322A1 (en) * | 2021-08-06 | 2023-02-09 | Actinium Pharmaceuticals, Inc. | Radioconjugates targeting cd33 in the treatment of cancers |
| AR127162A1 (es) * | 2021-09-29 | 2023-12-27 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y baff-r |
| CN118251411A (zh) * | 2021-09-29 | 2024-06-25 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| JP2025508740A (ja) * | 2022-02-17 | 2025-04-10 | アノキオン・ソシエテ・アノニム | 抗ａｓｇｒ１ポリペプチドおよび免疫寛容のための使用 |
| WO2024249235A1 (en) * | 2023-06-01 | 2024-12-05 | Abbvie Inc. | Anti-human cd33 bet degrader antibody-drug conjugates |
| WO2025233431A1 (en) * | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001027279A1 (en) * | 1999-10-12 | 2001-04-19 | Cambridge Antibody Technology | Human anti-adipocyte monoclonal antibodies and their use |
| JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| SG11201604784XA (en) * | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
| SI3280441T1 (sl) * | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| AU2016276981B2 (en) * | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| HK1252675A1 (zh) * | 2015-06-12 | 2019-05-31 | Alector Llc | 抗cd33抗体及其使用方法 |
-
2019
- 2019-02-20 BR BR112020016944-7A patent/BR112020016944A2/pt not_active Application Discontinuation
- 2019-02-20 TW TW108105692A patent/TW201945390A/zh unknown
- 2019-02-20 JP JP2020566543A patent/JP7539840B2/ja active Active
- 2019-02-20 CA CA3091764A patent/CA3091764A1/en active Pending
- 2019-02-20 WO PCT/US2019/018748 patent/WO2019164929A1/en not_active Ceased
- 2019-02-20 CN CN201980025297.8A patent/CN111989109A/zh active Pending
- 2019-02-20 EP EP19757093.0A patent/EP3755348A4/en active Pending
- 2019-02-20 PE PE2020001434A patent/PE20211224A1/es unknown
- 2019-02-20 SG SG11202007943RA patent/SG11202007943RA/en unknown
- 2019-02-20 EA EA202091976A patent/EA202091976A1/ru unknown
- 2019-02-20 US US16/971,098 patent/US20200376034A1/en not_active Abandoned
- 2019-02-20 AU AU2019225740A patent/AU2019225740A1/en not_active Abandoned
- 2019-02-20 MX MX2020008683A patent/MX2020008683A/es unknown
- 2019-02-20 KR KR1020207026825A patent/KR20200133222A/ko active Pending
-
2020
- 2020-08-18 IL IL276776A patent/IL276776A/en unknown
- 2020-08-19 CL CL2020002143A patent/CL2020002143A1/es unknown
-
2023
- 2023-07-19 CL CL2023002105A patent/CL2023002105A1/es unknown
-
2024
- 2024-08-14 JP JP2024135326A patent/JP2024170430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514206A5 (https=) | ||
| EP3341020B1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| RU2457219C2 (ru) | Антигенсвязывающие молекулы, которые связывают рецептор эпидермального фактора роста (egfr), кодирующие их векторы и их применение | |
| US11639388B2 (en) | CD3 antigen binding fragment and application thereof | |
| CN113015749A (zh) | 靶向cd3的抗体、双特异性抗体及其用途 | |
| AU2020344237A1 (en) | Anti-PD-L1 single-domain antibody and derivatives and use thereof | |
| CA3092456A1 (en) | Anti-tigit antibody and use thereof | |
| JP2023511482A (ja) | Ｃｄ２７６抗原の抗体ターゲティング、および他のモジュレーター、ならびにその使用 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2008529489A5 (https=) | ||
| EP3882276A1 (en) | Bispecific antibody, preparation method therefor and application thereof | |
| CN119161491A (zh) | 双特异性重组蛋白及其应用 | |
| JP2020527136A (ja) | チェックポイントインヒビター二重特異性抗体 | |
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| WO2017071625A1 (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
| JP2013528357A5 (https=) | ||
| JP2018506277A5 (https=) | ||
| CN111182919A (zh) | 抗cd137抗体 | |
| JP7495409B2 (ja) | 改善された抗ｆｌｔ３抗原結合タンパク質 | |
| AU2016319433A1 (en) | Anti-EphA4 antibody | |
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| KR20250130296A (ko) | 항-ccr8 항체 및 이의 용도 | |
| CN115340606A (zh) | 与人lag-3蛋白结合的抗体及其编码基因和应用 | |
| JP2019516360A (ja) | ヒト化抗ｒａｇｅ抗体 |